- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:58 | Bluebird bio's LentiGlobin gene therapy shows significant effect in SCD study | - | Seeking Alpha | ||
| Sa | Epizyme's tazemetostat shows positive action in mid-stage FL study | 1 | Seeking Alpha | ||
| Sa | XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B | 9 | Seeking Alpha | ||
| Sa | Unum Therapeutics Inc.: Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual ... | 1 | GlobeNewswire (USA) | ||
| Sa | Bluebird Sickle Cell Gene Therapy Ends Painful Attacks for Some | 6 | BNN Bloomberg | ||
| Sa | Autolus Limited: Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy ... | - | GlobeNewswire (USA) | ||
| Sa | Why Biogen's Alzheimer's Drug Presentation Left Investors Uninspired | 9 | The Motley Fool | ||
| Sa | Aptose Biosciences, Inc.: Aptose Presents Highlights From Corporate Event At ASH | 1 | GlobeNewswire (USA) | ||
| Sa | Principia Biopharma Inc.: Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in ... | 2 | GlobeNewswire (USA) | ||
| Sa | Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting | 3 | CNW | ||
| Sa | Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 | 385 | PR Newswire | STOCKHOLM, Dec. 7, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting... ► Artikel lesen | |
| Sa | Immunomedics: Updates To Thesis, Buy The Secondary | 6 | Seeking Alpha | ||
| Sa | Karyopharm Therapeutics Inc.: Karyopharm Reports New and Updated XPOVIO (Selinexor) Data in Relapsed or Refractory ... | 2 | GlobeNewswire (USA) | ||
| Sa | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase ... | 1 | GlobeNewswire (USA) | ||
| Sa | ONCOPEPTIDES AB: Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019 | - | Cision News | ||
| Sa | Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment | 499 | Business Wire | The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively
- All five patients... ► Artikel lesen | |
| Sa | Fate Therapeutics, Inc.: Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever ... | - | GlobeNewswire (USA) | ||
| Sa | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at ... | 2 | GlobeNewswire (USA) | ||
| Sa | Molecular Partners AG: Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting | 374 | ACCESSWIRE | Poster highlights Overall Response Rate (ORR) of 45% in heavily pretreated MM population
Strong evidence of durable and deepening responses with ongoing treatment in excess of 9 months in multiple... ► Artikel lesen | |
| Sa | Aufreger bei Wirecard, Evotec, Zooplus etc | 2.194 | Nebenwerte Magazin | Weihnachtszeit - gibt es noch so etwas wie eine Jahresendralley? Wenn dann wohl Anfang Dezember, oder? Am Sonntag spekulierten wir darüber, was ADO Properties wohl mit dem GEWOBAG-Geldsegen, der am... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| EVOTEC | 3 | 51 | +1,24 % | Biotech Report: Evotec (EVT) und MorphoSys (MOR) unter Druck | (shareribs.com) Frankfurt / New York 02.12.2019 - Biotech-Aktien zeigen sich zum Wochenauftakt überwiegend leichter. Nach unten geht es unter anderem für Evotec und MorphoSys. An der Wall Street kommt... ► Artikel lesen | ||
| BLUEBIRD BIO | 2 | 7 | +0,19 % | Bluebird bio's LentiGlobin gene therapy shows significant effect in SCD study | |||
| ONCOPEPTIDES | 2 | 6 | +6,56 % | Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 | STOCKHOLM, Dec. 7, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting... ► Artikel lesen | ||
| XBIOTECH | 2 | 2 | +5,58 % | XBiotech Inc.: XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen | XBiotech will continue its True Human anti IL-1? antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for JanssenAUSTIN,... ► Artikel lesen | ||
| BIOGEN | 1 | 61 | +0,89 % | Biogen-Aktie drohen Verluste! | Milwaukee (www.aktiencheck.de) - Biogen-Aktienanalyse von Analyst Brian Skorney von Robert W. Baird: Laut einer Aktienanalyse rechnet Brian Skorney, Analyst von Robert W. Baird, in Bezug auf die Aktien... ► Artikel lesen | ||
| MORPHOSYS | 1 | 38 | +2,41 % | Tagesausblick für 3.12.: DAX bricht ein. Morphosys, RWE und Varta im Fokus! | Richard Pfadenhauer,HypoVereinsbank onemarketsAuch heute gelang es dem DAX nicht, die Marke von 13.300 Punkten nachhaltig zu überwinden. Vielmehr sackte der Index in der zweiten Tageshälfte deutlich... ► Artikel lesen | ||
| IMMUNOMEDICS | 1 | 12 | +8,10 % | Immunomedics: Updates To Thesis, Buy The Secondary | |||
| XENON PHARMACEUTICALS | 1 | 8 | +3,31 % | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at ... | |||
| EPIZYME | 1 | 4 | +18,84 % | Epizyme's tazemetostat shows positive action in mid-stage FL study | |||
| APTOSE BIOSCIENCES | 1 | 4 | -2,59 % | Aptose Biosciences, Inc.: Aptose Presents Highlights From Corporate Event At ASH |
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| CYTOTOOLS AG | 11,000 | 27,80 | +153 % | 2 | - | - | |||
| MEDIGENE AG | 5,500 | 11 | +100 % | - | 1 | - | |||
| BIOFRONTERA AG | 4,540 | 6,60 | +45 % | 2 | - | - | |||
| EVOTEC SE | 20,330 | 26,50 | +30 % | 8 | - | - | |||
| MARINOMED BIOTECH AG | 103,00 | 133 | +29 % | 1 | - | - | |||
| MORPHOSYS AG | 118,90 | 126,33 | +6 % | 16 | 6 | - | |||
| QIAGEN NV | 37,990 | 34,07 | -10 % | 9 | 11 | 1 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
